Human iPSC-Derived Model Unlocks the Science of Itch 🔬 A team of researchers at IMCB, led by Dr. Shi Yan Ng and Dr. Boon Seng Soh, has developed a human iPSC-derived sensory neuron model to uncover the mechanisms behind histamine-induced itch. Through advanced techniques such as calcium imaging and multielectrode array analyses, the team demonstrated TRPV1’s role downstream of H1 receptors in pruritus, highlighting TRPV1 antagonists as potential therapeutic solutions. Kudos to the team for their impactful work! Check out the study at https://lnkd.in/gUt7_hQZ #IMCBscience #IMCBastar #Neurobiology #iPSC #SensoryNeuronModel #TRPV1 #ItchResearch
Institute of Molecular and Cell Biology (IMCB)
Biotechnology Research
Singapore, Singapore 4,672 followers
An international hub for biomedical research, development and innovation
About us
The Institute of Molecular and Cell Biology (IMCB) is a premier research institute at A*STAR whose mission is to harness biology for transformational bio-therapeutics and diagnostics. With a strong emphasis on collaboration with stakeholders across the ecosystem in Singapore, IMCB aims to achieve scientific excellence and continues to nurture the next generation of scientists in order to create growth and enhance lives.
- Website
-
https://www.a-star.edu.sg/imcb
External link for Institute of Molecular and Cell Biology (IMCB)
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Singapore, Singapore
- Type
- Government Agency
- Founded
- 1985
- Specialties
- cell biology, molecular biology, cell therapy, cancer signalling, neurometabolism, molecular therapeutics, proteomics, organoid models, preclinical models, and imaging
Locations
-
Primary
Get directions
61 Biopolis Dr, Proteos
Singapore, Singapore 138668, SG
Employees at Institute of Molecular and Cell Biology (IMCB)
-
Ajay Mathuru
Neuroscientist, Assoc. Professor| Dept. of Physiology, NUS | Yale-NUS College | Principal Investigator @ WisDM and HL TRPs | Joint PI, IMCB, A*STAR.
-
Cathleen Teh
Senior Research Fellow at Institue of Molecular and Cell Biology
-
Srivani Sistla
Be yourself. Everyone else is taken
-
Adrian Teo
Senior Principal Investigator l Associate Professor l Director of Graduate Affairs l Biotech
Updates
-
Institute of Molecular and Cell Biology (IMCB) reposted this
#Hiring #StemCellCareer #NickBarkerLab #IMCB #AStar 🔴 Exciting Opportunity: Research Officer (@Nick Barker Lab) at IMCB 🔴 Are you passionate about biology and ready to make a real impact in scientific research? The Institute of Molecular and Cell Biology (IMCB) is looking for a motivated RESEARCH OFFICER to join our STEM CELLS & CANCER Research Group! This is your chance to be part of a dynamic team pushing the boundaries of scientific discovery. What You'll Do? 🔬 Support Cutting-Edge Research 🧬 Assist our research fellows with tasks like tissue processing, histology, cell culture, and experimental mouse procedures. 🧬 Help with general lab operations and keep things running smoothly. 🐭 Work with Mice: 🧬 Help manage our mouse colony, including breeding, weaning and other key tasks (don’t worry—we’ll provide all the training you need!). 🧬 Take charge of these responsibilities independently after training. What We're Looking For: 🎓 Your Background: A degree in Biological Sciences, Life Sciences, or a related field. 🐭 Experience with Mice: Previous experience is a bonus but not essential. What matters most is your willingness to learn and be part of a great team! 🌟 Who You Are: Organized, self-motivated, and a great team player with a genuine enthusiasm for research. If you’re excited about science and eager to dive into impactful research, apply now to join our team! ➡️ How to Apply: https://lnkd.in/g8Q4pv3y Learn More About Us: https://lnkd.in/g83_FMrN. Nickbarkerlab.com
This content isn’t available here
Access this content and more in the LinkedIn app
-
🌟 Join Us for the Inaugural Panakeia Mini-Symposium 2025! 🌟 📅 Date: Thursday, 23rd January 2025 🕒 Time: 8:30am – 3:00pm 📍 Venue: Scorpio & Taurus, Level 2, Park Avenue Rochester Hotel To kick start the year, IMCB is proud to host this symposium, which addresses the critical need for scalable, off-the-shelf, and cost-effective immune cell therapies for cancer patients. This national platform brings together world-class experts in T/NK cell biology, genome editing, immunotherapy, GMP production, and clinical oncology to advance innovative CAR-NK products for immunotherapies. 💡 Featured IMCB Speakers from the Panakeia Program: · Prof Qi-Jing Li – Lead PI · Prof Loh Yuin-Han Jonathan – Co-Lead PI · Prof John Connolly · Prof Qi Zeng · Dr. Qingfeng Chen A big thank you to our exclusive sponsor, Thermo Fisher Scientific, for their support. 🔗 Register now (free registration) via the QR code, and see you there! #IMCBscience #IMCBastar #PanakeiaProgram #CancerImmunotherapy #CAR_NKCells
-
-
🎉 Happy New Year 2025 from IMCB! 🎉 As we step into another exciting year, IMCB wish you and your loved ones a year filled with happiness, health, and success. Here’s to another year of inspiring discoveries, collaborations, and breakthroughs in science! #HappyNewYear2025 #IMCBscience #IMCBastar
-
-
Wishing everyone a Merry Christmas filled with joy, peace, and love! 🎄✨ May this festive season bring warmth to your homes and happiness to your hearts. Thank you for being a part of our journey this year. #MerryChristmas #HappyHolidays #FestiveSeason #IMCBscience #IMCBastar
-
-
Institute of Molecular and Cell Biology (IMCB) reposted this
🎉 Reflecting on a Remarkable Year at IMCB! 🎉 As 2024 comes to a close, we take this opportunity to celebrate a year of impactful science, meaningful collaborations, and significant recognitions at IMCB. Here are some highlights: 🤝 Driving Innovation Through Strategic Collaborations ✅ Albatroz Therapeutics, an IMCB spin-off, is advancing antibody-drug conjugates (ADCs) targeting cancer and arthritis, translating years of foundational research into potential breakthrough therapies. ✅ IMCB partnered with Cerecin Inc. to accelerate research in neurometabolism and brain health, addressing the high unmet need in neurological diseases for Singapore’s aging population. ✅ IMCB scientists played a pivotal role in the NRF Competitive Research Programme project SPECTRA, focusing on spatial multi-omics cartography to guide the development of next-generation cell-based therapies. 🏆 Celebrating Talent and Excellence ➡️ Dr. Leslie Beh (NRF Fellowship 2024) for advancing RNA modification research, opening doors to novel therapeutic applications. ➡️ Dr. Qi-Jing Li (NRF Investigator 2024) for harnessing resident memory T cells to prevent breast cancer metastasis. ➡️ Dr. Shi Yan Ng (NMRC Open Fund) for her innovative work on lipid metabolism and neurodegeneration. 🌟 Showcasing Scientific Excellence 🧬 Dr. Christopher John Brown and collaborators developed new rules for designing low-toxicity peptide-based drugs, enhancing potency and safety for future therapeutics. 🧬 Dr. Qi-Jing Li, in collaboration with international teams, identified nerve growth factor (NGF) as a key immune suppressor in melanoma. Targeting NGF enhances immune checkpoint therapy, paving the way for improved treatments for skin cancer. ✨ Looking Ahead 2024 has been a transformative year, and we are excited to build on these achievements in 2025. IMCB remains committed to advancing biomedical research, fostering impactful collaborations, and delivering solutions to improve human health. Here’s to continued innovation and excellence in the year ahead! 🚀 #IMCBScience #IMCBastar #ScientificExcellence #InnovationInBiomedicine #Neurometabolism #CancerResearch #PeptideTherapeutics #EndOfYearReflection #BiomedicalInnovation #CellTherapy #CollaborationMatters
-
-
Learn more about how spatial biology technologies can shed light on the cell-cell interactions between stromal cells and the immune system in pancreatic cancer. Lead author Rachel Fincham shared: "Our exciting findings highlight the prognostic implications of stromal-natural killer cell proximity in pancreatic cancer. Taken together, we suggest the potential for spatial biology to be used as a tool for patient stratification in pancreatic cancer." #spatialbiology #diagnostictools #pancreaticcancer #cancerdetection #crossbordercollaborations
The relationship the immune system and stromal cells in pancreatic cancer can have a significant impact on patients’ survival rates, according to findings of Queen Mary-led study. Pancreatic ductal adenocarcinoma (PDAC) is the most common form of pancreatic cancer. It is highly aggressive due to its late presentation and poor response to therapy, with five-year survival rates remaining around 10%. PDAC is set to become the second leading cause of cancer-related deaths in the US by 2040, and therefore finding improved treatments for this disease is becoming increasingly critical. A study carried out by Rachel Fincham, a doctoral student under the guidance of Hemant Kocher, Professor of Liver and Pancreas Surgery at Queen Mary University of London and Barts Health NHS Trust, has found that treatment targeting the non-tumour, ‘stromal’ cells in pancreatic cancer with an aim of reverting them to a resting state can improve patient outcome. The study investigated the potential interactions between these stromal cells (also known as pancreatic stellate cells or cancer associated fibroblasts) and a specific type of immune cells called natural killer (NK) cells. Results from cell line experiments, mouse models, and samples from patient tissues, perform in London and Singapore (under guidance of Dr Joe Yeong) showed that exposing NK cells to resting stromal cells significantly decreased their capacity to attack pancreatic cancer cells. The study also demonstrated significant bi-directional interaction between NK and stromal cells and found that co-culturing these cell types significantly, and reciprocally, modulated their phenotype and altered their biological pathways. In mouse models, the study also found that standard therapeutic regimes caused striking differences in the spatial distribution of NK cells. Importantly, assessment of patient samples showed that having greater distance between NK cells and the cancer’s stromal cells was associated with people who had survived this type of cancer for longer. This research was conducted by researchers from Barts Cancer Institute (Queen Mary University of London), the Institute of Molecular and Cell Biology (IMCB), the Centre for Quantitative Medicine, Duke-National National University of Singapore (NUS) Medical School, the Department of Anatomical Pathology, Singapore General Hospital, the Cancer Science Institute of Singapore, National University of Singapore, and the Barts and the London Hepato-Pancreato-Biliary (HPB) Centre, Barts Health NHS Trust. Read more in the link in the comments, below.
-
-
🎉 Reflecting on a Remarkable Year at IMCB! 🎉 As 2024 comes to a close, we take this opportunity to celebrate a year of impactful science, meaningful collaborations, and significant recognitions at IMCB. Here are some highlights: 🤝 Driving Innovation Through Strategic Collaborations ✅ Albatroz Therapeutics, an IMCB spin-off, is advancing antibody-drug conjugates (ADCs) targeting cancer and arthritis, translating years of foundational research into potential breakthrough therapies. ✅ IMCB partnered with Cerecin Inc. to accelerate research in neurometabolism and brain health, addressing the high unmet need in neurological diseases for Singapore’s aging population. ✅ IMCB scientists played a pivotal role in the NRF Competitive Research Programme project SPECTRA, focusing on spatial multi-omics cartography to guide the development of next-generation cell-based therapies. 🏆 Celebrating Talent and Excellence ➡️ Dr. Leslie Beh (NRF Fellowship 2024) for advancing RNA modification research, opening doors to novel therapeutic applications. ➡️ Dr. Qi-Jing Li (NRF Investigator 2024) for harnessing resident memory T cells to prevent breast cancer metastasis. ➡️ Dr. Shi Yan Ng (NMRC Open Fund) for her innovative work on lipid metabolism and neurodegeneration. 🌟 Showcasing Scientific Excellence 🧬 Dr. Christopher John Brown and collaborators developed new rules for designing low-toxicity peptide-based drugs, enhancing potency and safety for future therapeutics. 🧬 Dr. Qi-Jing Li, in collaboration with international teams, identified nerve growth factor (NGF) as a key immune suppressor in melanoma. Targeting NGF enhances immune checkpoint therapy, paving the way for improved treatments for skin cancer. ✨ Looking Ahead 2024 has been a transformative year, and we are excited to build on these achievements in 2025. IMCB remains committed to advancing biomedical research, fostering impactful collaborations, and delivering solutions to improve human health. Here’s to continued innovation and excellence in the year ahead! 🚀 #IMCBScience #IMCBastar #ScientificExcellence #InnovationInBiomedicine #Neurometabolism #CancerResearch #PeptideTherapeutics #EndOfYearReflection #BiomedicalInnovation #CellTherapy #CollaborationMatters
-
-
🧬 How do new integrase variants transform genome editing? A recent study led by Senior Investigator Farid John Ghadessy and his team at IMCB has unveiled significant advancements in DNA editing. Their study introduces novel lambda integrase variants that show more than a 1000-fold improvement in specificity for non-natural target sites. These breakthroughs hold potential for advancing biomanufacturing by enabling precise genome editing in microorganisms such as Phaeodactylum tricornutum and Nannochloropsis oceanica. Notably, the integrases also successfully target unique sequences in the human genome, presenting exciting possibilities for gene therapy and genomic research. This work represents a critical step forward in precision genome engineering, with broad implications for both biotechnology and healthcare. Check out the exciting study 👉 https://lnkd.in/guNkNC6S #IMCBastar #IMCBscience #GenomeEditing #Biotechnology #PrecisionMedicine #GeneTherapy #DNAResearch #SyntheticBiology #SustainableBiotech #ResearchInnovation
Expanding the DNA editing toolbox: Novel lambda integrase variants targeting microalgal and human genome sequences
journals.plos.org
-
🔬 New Insights into Early Embryo Development Dr. Jonathan Yuin-Han Loh and team at IMCB have recently unveiled a key discovery in stem cell research. Their study, published in Nature Communications, identifies Nr1h2 as a critical transcription factor in early embryo development. This research sheds light on the genetic regulation during blastoid formation, offering promising insights for advancements in regenerative medicine, fertility treatments, and developmental biology. By activating Nr1h2, embryonic stem cells can transition into an expanded pluripotent state, enabling more robust models for studying early development and therapeutic targets. Dr. Loh emphasized how this finding improves the fidelity of embryo models and could help address challenges such as developmental disorders and infertility. Check out the exciting study and its impact here: https://lnkd.in/gHFRQ-HA #IMCBscience #IMCBastar #StemCellBiology #DevelopmentalBiology #RegenerativeMedicine
-